These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3308477)

  • 1. Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
    Roila F; Tonato M; Basurto C; Minotti V; Ballatori E; del Favero A
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):615-7. PubMed ID: 3308477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
    Roila F; Basurto C; Minotti V; Ballatori E; Tonato M; Del Favero A
    Oncology; 1988; 45(5):346-9. PubMed ID: 3412741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents.
    Basurto C; Roila F; Bracarda S; Tonato M; Ballatori E; Del Favero A
    Am J Clin Oncol; 1988 Oct; 11(5):594-6. PubMed ID: 3177262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study.
    Gez E; Sulkes A; Ochayon L; Gera C; Nathan S; Cass Y; Rubello E; Biran S
    J Chemother; 1989 Dec; 1(6):365-8. PubMed ID: 2693621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.
    Gez E; Strauss N; Vitzhaki N; Cass Y; Edelmann DZ
    Cancer Chemother Pharmacol; 1992; 30(3):229-32. PubMed ID: 1628373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiemetic activity of high-dose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients. A randomized double-blind study of the Italian Oncology Group for Clinical Research.
    Basurto C; Roila F; Tonato M; Ballatori E; Buzzi F; Calabresi F; Del Favero A
    Am J Clin Oncol; 1989 Jun; 12(3):235-8. PubMed ID: 2729180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo.
    Pollera CF; Nardi M; Marolla P; Pinnaró P; Terzoli E; Giannarelli D
    Am J Clin Oncol; 1989 Dec; 12(6):524-9. PubMed ID: 2589233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: a randomized trial.
    Campora E; Chiara S; Bruzzi P; Scarsi P; Rosso R
    Tumori; 1985 Oct; 71(5):459-62. PubMed ID: 3904102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
    Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
    Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.
    Roila F; Tonato M; Basurto C; Bella M; Passalacqua R; Morsia D; DiCostanzo F; Donati D; Ballatori E; Tognoni G
    J Clin Oncol; 1987 Jan; 5(1):141-9. PubMed ID: 3543234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
    Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
    N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis.
    Sabbatini R; Federico M; Baldini L; Barbieri F; Maiolo MT; Silingardi V
    Haematologica; 1995; 80(5):416-20. PubMed ID: 8566881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
    Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
    Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research.
    Roila F; Tonato M; Basurto C; Picciafuoco M; Bracarda S; Donati D; Malacarne P; Monici L; Di Costanzo F; Patoia L
    J Clin Oncol; 1989 Nov; 7(11):1693-700. PubMed ID: 2681556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the antiemetic activity of bromopride in cancer patients treated with i.v. CMF.
    Roila F; Minotti V; Ballatori E; Basurto C; Tonato M
    Tumori; 1985 Oct; 71(5):455-8. PubMed ID: 3840612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained-release metoclopramide plus methylprednisolone versus placebo plus methylprednisolone as antiemetic prophylaxis during non-cisplatin chemotherapy. A randomized double-blind cross-over trial.
    Hansen O; Pfeiffer P; Madsen B; Andersen I; Hansen B; Mathiesen B
    Acta Oncol; 1996; 35(1):57-61. PubMed ID: 8619941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylprednisolone for the control of CMF-induced emesis.
    Chiara S; Campora E; Lionetto R; Bruzzi P; Rosso R
    Am J Clin Oncol; 1987 Jun; 10(3):264-7. PubMed ID: 3296735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind randomized cross-over trial comparing methylprednisolone with placebo in chemotherapy-induced nausea and vomiting: a study with special reference to efficacy parameters.
    Havsteen H; Kjaer M
    Anticancer Drugs; 1991 Dec; 2(6):571-9. PubMed ID: 1806034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients.
    Roila F; Bracarda S; Basurto C; Sassi M; Lupattelli M; Picciafuoco M; Boschetti E; Del Favero A; Tonato M
    Am J Clin Oncol; 1992 Apr; 15(2):112-4. PubMed ID: 1553897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.